[Updated on Apr. 18] Integration of CiNii Articles into CiNii Research

Expert Opinions on the Current Therapeutic Management of Inflammatory Bowel Disease During the COVID-19 Pandemic: JAPAN IBD COVID-19 TASKFORCE, Intractable Diseases, the Health and Labor Sciences Research

DOI
  • Nakase Hiroshi
    Department of Gastroenterology and Hepatology, Sapporo Medical University School of Medicine
  • Matsumoto Takayuki
    Division of Gastroenterology, Department of Medicine, Iwate Medical University
  • Matsuura Minoru
    Department of Gastroenterology and Hepatology, Kyorin University School of Medicine
  • Iijima Hideki
    Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine
  • Matsuoka Katsuyoshi
    Department of Gastroenterology and Hepatology, Toho University Sakura Medical Center
  • Ohmiya Naoki
    Department of Gastroenterology, Fujita Health University School of Medicine
  • Ishihara Shunji
    Department of Gastroenterology, Faculty of Medicine, Shimane University
  • Hirai Fumihito
    Department of Gastroenterology and Medicine, Fukuoka University Faculty of Medicine
  • Wagatsuma Kouhei
    Department of Gastroenterology and Hepatology, Sapporo Medical University School of Medicine
  • Yokoyama Yoshihiro
    Department of Gastroenterology and Hepatology, Sapporo Medical University School of Medicine
  • Hisamatsu Tadakazu
    Department of Gastroenterology and Hepatology, Kyorin University School of Medicine

Bibliographic Information

Other Title
  • COVID-19パンデミック状況下における炎症性腸疾患の管理に関する専門家の意見 JAPAN IBD COVID-19 TASKFORCE:厚生労働科学研究費補助金(難治性疾患政策研究事業)難治性炎症性腸管障害に関する調査研究班

Search this article

Abstract

<p>The COVID-19 pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has influenced all medical systems. This outbreak immediately affected gastroenterologists as well as global physicians worldwide. However, the comorbidity spectrum of digestive system in patients with COVID-19 remains unknown. Additionally, there are few data on the risk of SARS-CoV-2 infection and COVID-19 aggravation in inflammatory bowel disease (IBD). Physicians and patients have great concern about whether IBD patients are more susceptible to SARS-CoV-2 infection and have worsened disease courses. Therefore, it is necessary to precisely ascertain the risk of SARS-CoV-2 infection and the COVID-19 severity in IBD patients and to acknowledge the IBD management during the COVID-19 pandemic with clinically reliable information from COVID-19 cohorts and IBD experts' opinions.</p><p>In this review, we highlight gastrointestinal symptoms in COVID-19 and clinical questions regarding IBD management during the COVID-19 pandemic and make comments corresponding to each question based on recent publications. At the moment, we propose four key points as follows: (1) no evidence that IBD itself increases the risk of SARS-CoV-2 infection, (2) to basically prioritize the control of disease activity of IBD, (3) no need for physicians to suddenly discontinue immunomodulatory or biologic therapy in patients with quiescent IBD, and (4) a need for careful observation of elderly (>60 years old) and IBD patients receiving corticosteroid treatment during the COVID-19 pandemic.</p>

Journal

Details

Report a problem

Back to top